Successful treatment of resistant pseudogout with anakinra.

Abstract

We describe herein the case of a 63-year-old man with pseudogout affecting multiple joints that was resistant to treatment with allopurinol, steroids, and antiinflammatory drugs. Based on recent data on the molecular mechanism of pseudogout that demonstrated overproduction of interleukin-1 (IL-1), we treated the patient with anakinra, an IL-1 receptor antagonist. The patient responded to treatment with anakinra within 2 weeks, with resolution of the signs and symptoms of pseudogout and normalization of levels of inflammation markers.

• Authors: Dennis McGonagle, Ai Lyn Tan, Julie Madden, Paul Emery, Michael F McDermott
• Journal: Arthritis and rheumatism (Arthritis Rheum) Vol. 58 Issue 2 Pg. 631-3 (Feb 2008) ISSN: 0004-3591 [Print] United States
• PMID: 18240249 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antirheumatic Agents
• Biomarkers
• Interleukin 1 Receptor Antagonist Protein

Topics

• Antirheumatic Agents (administration & dosage)
• Biomarkers
• Chondrocalcinosis (drug therapy, immunology, pathology)
• Female
• Humans
• Interleukin 1 Receptor Antagonist Protein (administration & dosage)
• Middle Aged